Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 778 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Not listed No phase listed Observational Accepts healthy volunteers

S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues

NCT04666532
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Terminated Phase 4 Interventional Results available

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View directory record Official record
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions
Bezlotoxumab, Normal Saline
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

NCT01453907
View directory record Official record
Conditions
Anthrax
Interventions
ETI-204, "Anthim", placebo
Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Taking of blood samples, Boostrix, Adacel
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years to 73 Years
Enrollment
1,954 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
37
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

NCT03615482
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, QIV, Matching Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 23, 2026, 5:25 PM EDT
Recruiting Phase 2Phase 3 Interventional

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant

NCT05695196
View directory record Official record
Conditions
Staphylococcus Aureus, Microbial Colonization, Neonatal Infection
Interventions
nasal microbiota transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome

NCT06283355
View directory record Official record
Conditions
Staphylococcus Aureus, Microbial Colonization, Neonatal Infection
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 23, 2026, 5:25 PM EDT
Recruiting No phase listed Observational

Fecal Microbiota Transplant National Registry

NCT03325855
View directory record Official record
Conditions
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Interventions
None - Observational
Other
Lead sponsor
American Gastroenterological Association
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
52
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology

NCT04940468
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection, Solid Cancers
Interventions
Diet Intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Nutrition, Immunology and Epidemiology of Tuberculosis

NCT00197704
View directory record Official record
Conditions
Tuberculosis
Interventions
Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 23, 2026, 5:25 PM EDT
Completed No phase listed Observational

Effect of Filarial Infection on Immune Responses in Latent Tuberculosis

NCT01547884
View directory record Official record
Conditions
Mycobacterium Infections, Tuberculosis, Filariasis, Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4,268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 23, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 5:25 PM EDT
Completed No phase listed Observational

Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections

NCT01198262
View directory record Official record
Conditions
Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 23, 2026, 5:25 PM EDT